STAT

Opinion: The pharmaceutical industry is no stranger to fake news

I've been investigating the shadowy world of product defense, an early form of fake news, for years. It's still going on.
Tactics created and honed by the tobacco industry for "product defense" have been used by the pharmaceutical, chemical, and other industries.

Accusations of “fake news” are all the rage now, with people often throwing around the term when they read an article that tells them something they don’t want to hear. But an entire industry called “product defense,” created years ago by the tobacco industry, uses falsehoods and misdirection to protect companies from bad media and regulatory scrutiny. The pharmaceutical industry is no stranger to these tactics.

Document archives have revealed how tobacco companies helped create and hone product defense strategies. In my years as a reporter and during a stint as an investigator for the U.S. Senate, I’ve seen them deployed by a range of industries.

I fell into this world back in 2005, while working as an editor for the news section of Environmental Science & Technology, the top journal in the field of environmental science. After spending weeks digging about Steven J. Milloy, a columnist for FoxNews.com who ran a website called JunkScience.com and headed a shady organization called The Advancement of Sound Science Coalition (TASSC). , the public relations firm APCO explained how it launched TASSC “to expand and assist Philip Morris in its efforts with issues in targeted states in 1994.”

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks